Papillary transitional cell carcinoma of bladder
Also known as: Superficial papillary bladder cancer / Urothelial carcinoma bladder / Bladder transitional cell carcinoma / Transitional cell carcinoma of bladder (disorder)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB00445 | Epirubicin | An anthracycline topoisomerase II inhibitor used as an adjuvant to treating axillary node metastases in patients who have undergone surgical resection of primary breast cancer. |
| DB04572 | Thiotepa | An alkylating agent used to prevent graft rejection in stem cell transplantation and to treat a variety of malignancies including certain types of adenocarcinoma and superficial bladder carcinomas. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB00445 | Epirubicin | DNA topoisomerase 2-alpha | target |
| DB00445 | Epirubicin | DNA | target |
| DB00445 | Epirubicin | Multidrug resistance-associated protein 1 | transporter |
| DB00445 | Epirubicin | UDP-glucuronosyltransferase 2B7 | enzyme |
| DB00445 | Epirubicin | Cytosolic phospholipase A2 | enzyme |
| DB04572 | Thiotepa | Cytochrome P450 2B6 | enzyme |
| DB04572 | Thiotepa | Cytochrome P450 3A4 | enzyme |
| DB04572 | Thiotepa | DNA | target |
| DB04572 | Thiotepa | Cholinesterase | enzyme |
| Drug | Drug Name | Phase | Status | Count |
|---|